相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gapped sequence alignment using artificial neural networks: application to the MHC class I system
Massimo Andreatta et al.
BIOINFORMATICS (2016)
Pan-cancer analysis of the extent and consequences of intratumor heterogeneity
Noemi Andor et al.
NATURE MEDICINE (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study
Scott Antonia et al.
LANCET ONCOLOGY (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Automated benchmarking of peptide-MHC class I binding predictions
Thomas Trolle et al.
BIOINFORMATICS (2015)
Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
Nicholas McGranahan et al.
CANCER CELL (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Immunogenic peptide discovery in cancer genomes
Alexandra Snyder et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2015)
Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification
Massimo Andreatta et al.
IMMUNOGENETICS (2015)
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
Cyrille J. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Sebastian Kreiter et al.
NATURE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
Ayelet Sivan et al.
SCIENCE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing
Tyler S. Alioto et al.
NATURE COMMUNICATIONS (2015)
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma
Carsten Linnemann et al.
NATURE MEDICINE (2015)
Comparison of somatic mutation calling methods in amplicon and whole exome sequence data
Huilei Xu et al.
BMC GENOMICS (2014)
Deconstructing the Peptide-MHC Specificity of T Cell Recognition
Michael E. Birnbaum et al.
CELL (2014)
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
Scott D. Brown et al.
GENOME RESEARCH (2014)
Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication
Eve Shinbrot et al.
GENOME RESEARCH (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer
Eric Tran et al.
SCIENCE (2014)
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Pierre G. Coulie et al.
NATURE REVIEWS CANCER (2014)
The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes
Tae-Min Kim et al.
CELL (2013)
The cancer antigenome
Bianca Heemskerk et al.
EMBO JOURNAL (2013)
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
Nienke van Rooij et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Paul F. Robbins et al.
NATURE MEDICINE (2013)
Properties of MHC Class I Presented Peptides That Enhance Immunogenicity
Jorg J. A. Calis et al.
PLOS COMPUTATIONAL BIOLOGY (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Ramaswamy Govindan et al.
CELL (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hirokazu Matsushita et al.
NATURE (2012)
Expression of tumour-specific antigens underlies cancer immunoediting
Michel DuPage et al.
NATURE (2012)
How the TCR balances sensitivity and specificity for the recognition of self and pathogens
Gerald P. Morris et al.
NATURE IMMUNOLOGY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Jacques Neefjes et al.
NATURE REVIEWS IMMUNOLOGY (2011)
MHC Class II epitope predictive algorithms
Morten Nielsen et al.
IMMUNOLOGY (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
T Cell Activation
Jennifer E. Smith-Garvin et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Epitope landscape in breast and colorectal cancer
Neil H. Segal et al.
CANCER RESEARCH (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction
Mette V. Larsen et al.
BMC BIOINFORMATICS (2007)
NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence
Morten Nielsen et al.
PLOS ONE (2007)
Unique tumor antigens: Evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy
Marialuisa Sensi et al.
CLINICAL CANCER RESEARCH (2006)
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
V Lennerz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Cancer/testis antigens, gametogenesis and cancer
AJG Simpson et al.
NATURE REVIEWS CANCER (2005)
The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage
M Nielsen et al.
IMMUNOGENETICS (2005)
Persistence of multiple tumor-specific T-Cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy
JH Zhou et al.
JOURNAL OF IMMUNOTHERAPY (2005)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)
Reliable prediction of T-cell epitopes using neural networks with novel sequence representations
M Nielsen et al.
PROTEIN SCIENCE (2003)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer
I Saeterdal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens
M Linnebacher et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
